Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Etienne Nichols
What’s the difference?
Liza Dzhezhora
How to ensure the integration of IoMT devices in your practice
Del Williams
Options to address the risk of combustible dust explosions for NFPA 61 compliance
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind

More Features

FDA Compliance News
Creates one of the most comprehensive regulatory SaaS platforms for the industry
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community

More News

Quality Digest

FDA Compliance

FDA Clears Pulled Reprocessed Devices

Published: Tuesday, April 26, 2005 - 22:00

The Food and Drug Administration has determined that endoscopic trocars reprocessed by Vanguard Medical Concepts Inc. are substantially equivalent to new instruments and has cleared the company to resume selling them. Vanguard voluntary took its trocars off the market last fall, pending an FDA request for additional documentation of Vanguard’s methods for cleaning, testing and sterilizing the costly devices. At issue was whether the trocars, which are marketed for single use, could be safety reconditioned for a limited number of additional uses and function as new without patient health risks.

“We have always held ourselves to the most stringent cleaning, testing and sterilization standards,” says Charles Masek, president and CEO of Vanguard. “With today’s announcement, we have completed an unprecedented second round of intense regulatory scrutiny and passed with flying colors.”

Used to establish the path of entry for minimally invasive endoscopic surgical instruments, the vast majority of trocars are sold as single-use disposables. The average ECRI national selling price ranges from $27 to $64, and approximately $1 billion is spent on endoscopic trocars annually. The savings from reprocessing is approximately 50 percent more than the cost of a new device.

“We applaud the FDA’s aggressive stance on patient safety,” says Mac Brown, Vanguard executive vice president. “Given our proven understanding of the enhanced requirements of the FDA, look for us to significantly expand our already industry-leading product offerings in the future.”

For more information, visit www.safe-reuse.com.


About The Author

Quality Digest’s picture

Quality Digest

For 40 years Quality Digest has been the go-to source for all things quality. Our newsletter, Quality Digest, shares expert commentary and relevant industry resources to assist our readers in their quest for continuous improvement. Our website includes every column and article from the newsletter since May 2009 as well as back issues of Quality Digest magazine to August 1995. We are committed to promoting a view wherein quality is not a niche, but an integral part of every phase of manufacturing and services.